Allakos Stock Price. Everything You Need To Know About The Allakos Stock!
Allakos, Inc. engages in the development of therapeutic antibodies. The company is headquartered in San Carlos, California and currently employs 123 full-time employees. The company went IPO on 2018-07-19. The firm is developing therapeutics, which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory, and proliferative diseases. Its advanced antibodies are lirentelimab (AK002) and AK006. AK002 selectively targets both mast cells and eosinophils, two types of white blood cells that are distributed in the body and play a central role in the inflammatory response. The company is developing AK002 for the treatment of eosinophilic esophagitis (EoE), eosinophilic gastritis, eosinophilic duodenitis (EoD), atopic dermatitis, chronic spontaneous urticaria and additional indications. AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. The company is conducting pre-clinical studies with AK007, which is designed to block known ligand interaction with Siglec-10. The company is also developing additional antibodies targeting inhibitory receptors expressed on key disease-driving immune cells.
Allakos Stock Price. Everything You Need To Know About The Allakos Stock! performance
- Employees 123
- Company HQ San Carlos
- Website http://www.allakos.com/
- ALLK Asset Type Common Stock
- ALLK Market Capitalization 90.3M
- Earnings Per Share -2.14
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0
Investing in stocks is a wise financial decision that can help you build wealth over time. One stock that you should consider adding to your portfolio is Allakos. Allakos is a biotechnology company that focuses on developing innovative antibody-based therapeutics for various allergic and inflammatory diseases. With a strong pipeline of potential treatments, Allakos has captured the attention of investors in Malaysia, Thailand, Indonesia, and Vietnam. To invest in Allakos from these countries, you can use Zorion, an investment platform that offers real US stock and Pre-IPO company investment opportunities to retail investors. By signing up with Zorion, you will gain access to investment insights and recommendations specific to Allakos, enabling you to make informed decisions about your investments. Moreover, Zorion provides valuable resources and educational materials to empower retail investors from Malaysia, Thailand, Indonesia, and Vietnam. These resources aim to enhance your investment knowledge and help you navigate the stock market with confidence. Investing in Allakos can potentially yield significant returns in the long run. With Zorion as your trusted investment platform, you can seize this opportunity and start your journey towards financial success. Begin your investment in Allakos today and unlock the potential for future growth.
